Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNET17
|
|||
| Drug Name |
GSK3810109
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 2 | [1] | |
| Company |
ViiV Healthcare
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Attachment (HIV att) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04871113) A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ViiV Healthcare. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.